semaglutide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
glucagon-like peptide (GLP) analogues and agonists	5267	910463-68-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: rybelsus semaglutide NNC 0113-0217 ozempic wegovy	Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase. Molecular weight: 4113.64 Formula: C187H291N45O59 CLOGP: LIPINSKI: None HAC: 104 HDO: 57 TPSA: 1646.18 ALOGS: ROTB: 149

Molecule

Description

Molfile Inchi Smiles

Synonyms:

rybelsus
semaglutide
NNC 0113-0217
ozempic
wegovy

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation. Furthermore, semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner. Thus, when blood glucose is high, insulin secretion is stimulated and glucagon secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.

Molecular weight: 4113.64
Formula: C187H291N45O59
CLOGP:
LIPINSKI: None
HAC: 104
HDO: 57
TPSA: 1646.18
ALOGS:
ROTB: 149

Drug dosage:

Dose	Unit	Route
10.50	mg	O
0.11	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Bocci G, Oprea TI, Benet LZ

Approvals:

Date	Agency	Company
Feb. 8, 2018	EMA	Novo Nordisk A/S
Dec. 5, 2017	FDA	NOVO NORDISK INC
March 23, 2018	PMDA	Novo Nordisk Pharma Ltd

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pancreatitis	438.02	16.13	222	15394	48833	63424573
Nausea	380.22	16.13	716	14900	853755	62619651
Diabetic ketoacidosis	304.50	16.13	132	15484	20373	63453033
Vomiting	264.85	16.13	483	15133	559134	62914272
Euglycaemic diabetic ketoacidosis	143.65	16.13	48	15568	3626	63469780
Weight decreased	121.39	16.13	232	15384	276566	63196840
Blood glucose increased	110.61	16.13	119	15497	83637	63389769
Glycosylated haemoglobin increased	95.78	16.13	51	15565	12347	63461059
Inappropriate schedule of product administration	85.24	16.13	116	15500	103849	63369557
Heart sounds	81.73	16.13	23	15593	973	63472433
Prolonged expiration	79.55	16.13	23	15593	1073	63472333
Sleep disorder due to a general medical condition	77.25	16.13	44	15572	12144	63461262
Pancreatic carcinoma	75.24	16.13	37	15579	7591	63465815
COVID-19	74.85	16.13	114	15502	112989	63360417
Cholelithiasis	73.60	16.13	71	15545	43854	63429552
Decreased appetite	72.63	16.13	178	15438	250874	63222532
Drug dose titration not performed	70.34	16.13	18	15598	527	63472879
Ketoacidosis	67.61	16.13	29	15587	4349	63469057
Drug titration error	67.51	16.13	19	15597	804	63472602
Retinopathy	66.39	16.13	26	15590	3093	63470313
Diarrhoea	66.25	16.13	348	15268	715018	62758388
Dehydration	65.83	16.13	137	15479	173217	63300189
Blood glucose decreased	64.33	16.13	48	15568	20904	63452502
Diabetic retinopathy	62.54	16.13	23	15593	2304	63471102
Thyroid mass	61.81	16.13	27	15589	4231	63469175
Lipase increased	60.76	16.13	35	15581	9865	63463541
Product communication issue	57.17	16.13	16	15600	663	63472743
Depressive symptom	56.28	16.13	25	15591	4077	63469329
Eructation	55.28	16.13	31	15585	8302	63465104
Drug ineffective	55.20	16.13	109	15507	1044656	62428750
Product dispensing error	54.26	16.13	33	15583	10272	63463134
Off label use	53.60	16.13	315	15301	674147	62799259
Flank pain	51.28	16.13	38	15578	16372	63457034
Myoglobinuria	49.18	16.13	12	15604	288	63473118
Mesenteric panniculitis	48.29	16.13	10	15606	110	63473296
Hypoglycaemia	46.15	16.13	65	15551	60000	63413406
Respiration abnormal	45.66	16.13	25	15591	6392	63467014
Pancreatitis acute	45.66	16.13	44	15572	27122	63446284
Abdominal pain	43.05	16.13	164	15452	293292	63180114
Constipation	42.76	16.13	137	15479	224806	63248600
Impaired gastric emptying	41.75	16.13	28	15588	10304	63463102
Cholecystitis	40.14	16.13	32	15584	15345	63458061
Systemic lupus erythematosus	39.94	16.13	3	15613	208915	63264491
Nasal congestion	37.62	16.13	62	15554	65598	63407808
Appetite disorder	37.40	16.13	23	15593	7298	63466108
Medullary thyroid cancer	37.04	16.13	9	15607	212	63473194
Pneumonia	36.72	16.13	35	15581	456732	63016674
Toxicity to various agents	36.68	16.13	8	15608	247242	63226164
Injection site extravasation	35.82	16.13	24	15592	8817	63464589
Synovitis	34.85	16.13	3	15613	186915	63286491
Increased appetite	33.96	16.13	24	15592	9606	63463800
Glossodynia	32.99	16.13	3	15613	178873	63294533
Asthma	32.19	16.13	86	15530	127475	63345931
Arthropathy	32.10	16.13	9	15607	234783	63238623
Gastrointestinal disorder	31.63	16.13	87	15529	131152	63342254
Treatment failure	30.42	16.13	6	15610	199037	63274369
Contraindicated product administered	30.39	16.13	8	15608	217640	63255766
Rales	30.14	16.13	25	15591	12672	63460734
Neutropenia	29.59	16.13	4	15612	175001	63298405
Rheumatoid arthritis	29.11	16.13	13	15603	253806	63219600
Illness	29.01	16.13	47	15569	49012	63424394
Death	28.56	16.13	30	15586	374351	63099055
Product use in unapproved indication	27.81	16.13	102	15514	178978	63294428
Irregular sleep phase	27.77	16.13	5	15611	24	63473382
Hunger	27.74	16.13	17	15599	5362	63468044
Obstructive pancreatitis	26.85	16.13	8	15608	415	63472991
Vision blurred	26.31	16.13	65	15551	91859	63381547
Drug hypersensitivity	25.89	16.13	23	15593	310664	63162742
Lactic acidosis	25.87	16.13	39	15577	38248	63435158
Maculopathy	25.42	16.13	12	15604	2250	63471156
Therapeutic product effect decreased	25.31	16.13	8	15608	193179	63280227
Joint swelling	25.28	16.13	26	15590	327640	63145766
Exposure during pregnancy	25.26	16.13	4	15612	155543	63317863
Blood glucose abnormal	24.04	16.13	18	15598	7874	63465532
Abdominal distension	23.48	16.13	60	15556	86555	63386851
Thrombocytopenia	22.18	16.13	5	15611	151152	63322254
Urethral caruncle	22.18	16.13	5	15611	84	63473322
Abdominal pain upper	22.16	16.13	105	15511	206339	63267067
Glomerular filtration rate decreased	21.14	16.13	21	15595	13420	63459986
Diabetes mellitus inadequate control	20.83	16.13	22	15594	15104	63458302
Urine calcium/creatinine ratio increased	20.69	16.13	5	15611	115	63473291
Counterfeit product administered	20.57	16.13	4	15612	31	63473375
Headache	20.19	16.13	241	15375	633000	62840406
Stomatitis	19.55	16.13	5	15611	138720	63334686
Productive cough	19.48	16.13	46	15570	63162	63410244
Angina pectoris	19.41	16.13	30	15586	30048	63443358
Dermatitis atopic	18.74	16.13	17	15599	9707	63463699
Diabetes mellitus	18.72	16.13	42	15574	55768	63417638
Product label confusion	18.45	16.13	9	15607	1813	63471593
Urinary incontinence	18.02	16.13	30	15586	31984	63441422
Contraindicated product prescribed	17.93	16.13	8	15608	1317	63472089
Infection	17.87	16.13	18	15598	229155	63244251
Incorrect dose administered	17.78	16.13	43	15573	59925	63413481
Blister	17.68	16.13	5	15611	129809	63343597
Blood creatine increased	17.56	16.13	13	15603	5588	63467818
Bile duct stone	17.45	16.13	11	15605	3645	63469761
Chronic kidney disease	17.33	16.13	36	15580	45362	63428044
Reperfusion arrhythmia	17.17	16.13	5	15611	239	63473167
Oedema peripheral	17.05	16.13	13	15603	189498	63283908
Discomfort	17.05	16.13	10	15606	167364	63306042
Product prescribing error	16.66	16.13	26	15590	26263	63447143
Food craving	16.46	16.13	8	15608	1598	63471808
Blood creatine phosphokinase increased	16.44	16.13	28	15588	30402	63443004
Infusion related reaction	16.22	16.13	22	15594	245499	63227907

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Vomiting	536.11	20.37	482	9185	247139	34700125
Nausea	526.69	20.37	550	9117	339358	34607906
Pancreatitis	463.15	20.37	222	9445	38669	34908595
Diarrhoea	209.12	20.37	379	9288	389533	34557731
Euglycaemic diabetic ketoacidosis	176.93	20.37	56	9611	3166	34944098
Diabetic ketoacidosis	167.08	20.37	87	9580	17945	34929319
Eructation	122.74	20.37	47	9620	4684	34942580
Glycosylated haemoglobin increased	100.03	20.37	53	9614	11307	34935957
Weight decreased	91.85	20.37	170	9497	176131	34771133
Decreased appetite	88.62	20.37	162	9505	166230	34781034
Gastrointestinal disorder	86.32	20.37	73	9594	33875	34913389
Cholecystitis acute	83.23	20.37	39	9628	6400	34940864
Retinopathy	77.74	20.37	27	9640	2037	34945227
Abdominal pain	74.39	20.37	149	9518	163469	34783795
Blood glucose increased	68.18	20.37	88	9579	66630	34880634
Bile duct stone	64.68	20.37	25	9642	2552	34944712
Pancreatic carcinoma	63.10	20.37	36	9631	8865	34938399
Diabetic retinopathy	61.67	20.37	22	9645	1795	34945469
Constipation	60.12	20.37	123	9544	136859	34810405
Cholelithiasis	56.88	20.37	47	9620	21101	34926163
Pancreatitis acute	54.65	20.37	52	9615	28089	34919175
Abdominal discomfort	53.56	20.37	74	9593	59761	34887503
Vision blurred	52.30	20.37	64	9603	45899	34901365
Gastrooesophageal reflux disease	50.09	20.37	57	9610	37867	34909397
Obstructive pancreatitis	43.78	20.37	13	9654	591	34946673
Flatulence	42.74	20.37	40	9627	21158	34926106
Cholecystitis	42.52	20.37	30	9637	10658	34936606
Abdominal distension	41.71	20.37	65	9602	58427	34888837
Necrotising myositis	37.98	20.37	12	9655	673	34946591
Lipase increased	36.46	20.37	26	9641	9390	34937874
Dehydration	36.44	20.37	98	9569	129871	34817393
Ketoacidosis	35.10	20.37	19	9648	4224	34943040
Blood glucose decreased	34.71	20.37	29	9638	13208	34934056
Pneumonia	34.34	20.37	30	9637	362597	34584667
Abdominal pain upper	32.24	20.37	65	9602	71425	34875839
Drug dose titration not performed	32.10	20.37	9	9658	333	34946931
Inappropriate schedule of product administration	30.95	20.37	59	9608	62237	34885027
Neuropathy vitamin B12 deficiency	30.44	20.37	7	9660	114	34947150
Acute kidney injury	29.06	20.37	163	9504	304825	34642439
Dizziness	28.74	20.37	128	9539	218393	34728871
Gastric ischaemia	28.13	20.37	5	9662	19	34947245
Dyspepsia	27.83	20.37	42	9625	36690	34910574
Neutropenia	27.63	20.37	5	9662	156773	34790491
Febrile neutropenia	27.30	20.37	3	9664	136846	34810418
Impaired gastric emptying	27.28	20.37	15	9652	3438	34943826
Pharyngeal swelling	27.02	20.37	13	9654	2259	34945005
Dysmetria	26.94	20.37	9	9658	603	34946661
Vitreous haemorrhage	26.49	20.37	13	9654	2360	34944904
Glomerular filtration rate decreased	25.24	20.37	24	9643	12937	34934327
Medullary thyroid cancer	25.11	20.37	5	9662	39	34947225
Anaemia	24.97	20.37	17	9650	233318	34713946
Hiccups	24.21	20.37	21	9646	10061	34937203
Death	24.15	20.37	46	9621	398003	34549261
Vitamin B12 decreased	23.82	20.37	10	9657	1263	34946001
Hypoglycaemia	23.82	20.37	49	9618	54591	34892673
Therapeutic drug monitoring analysis incorrectly performed	23.52	20.37	7	9660	321	34946943
Diabetes mellitus inadequate control	22.62	20.37	23	9644	13441	34933823
Product communication issue	21.91	20.37	7	9660	407	34946857
Pancreatitis necrotising	21.84	20.37	12	9655	2746	34944518
Gait spastic	21.83	20.37	9	9658	1087	34946177
Product label confusion	21.35	20.37	6	9661	224	34947040
Lactic acidosis	21.18	20.37	36	9631	34736	34912528
General physical health deterioration	20.72	20.37	5	9662	128264	34819000

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Nausea	614.87	15.41	955	19098	956241	78768094
Vomiting	583.09	15.41	771	19282	665057	79059278
Diabetic ketoacidosis	377.14	15.41	180	19873	33942	79690393
Pancreatitis	376.43	15.41	227	19826	68348	79655987
Euglycaemic diabetic ketoacidosis	308.19	15.41	100	19953	6744	79717591
Diarrhoea	215.12	15.41	592	19461	879897	78844438
Glycosylated haemoglobin increased	146.54	15.41	79	19974	19181	79705154
Decreased appetite	144.43	15.41	286	19767	342132	79382203
Weight decreased	140.67	15.41	289	19764	354909	79369426
Eructation	131.03	15.41	61	19992	10848	79713487
Blood glucose increased	114.84	15.41	143	19910	114832	79609503
Cholelithiasis	109.57	15.41	97	19956	52567	79671768
Cholecystitis acute	90.81	15.41	51	20002	13400	79710935
Abdominal pain	86.57	15.41	254	19799	389315	79335020
Pancreatitis acute	85.01	15.41	82	19971	49522	79674813
Heart sounds	81.92	15.41	23	20030	943	79723392
Sleep disorder due to a general medical condition	80.10	15.41	48	20005	14229	79710106
Bile duct stone	78.96	15.41	35	20018	5554	79718781
Pancreatic carcinoma	77.09	15.41	46	20007	13531	79710804
Prolonged expiration	75.68	15.41	23	20030	1248	79723087
COVID-19	74.00	15.41	138	19915	157536	79566799
Dehydration	73.42	15.41	180	19873	248007	79476328
Ketoacidosis	70.51	15.41	36	20017	7818	79716517
Constipation	67.10	15.41	189	19864	282861	79441474
Inappropriate schedule of product administration	65.26	15.41	119	19934	133509	79590826
Drug titration error	64.82	15.41	20	20033	1142	79723193
Lipase increased	61.81	15.41	43	20010	16423	79707912
Cholecystitis	60.88	15.41	48	20005	22164	79702171
Drug ineffective	59.38	15.41	114	19939	1080799	78643536
Drug dose titration not performed	58.43	15.41	17	20036	793	79723542
Blood glucose decreased	57.92	15.41	50	20003	26184	79698151
Diabetic retinopathy	55.59	15.41	23	20030	3083	79721252
Hypoglycaemia	54.12	15.41	94	19959	101500	79622835
Obstructive pancreatitis	52.54	15.41	16	20037	874	79723461
Flatulence	50.60	15.41	58	19995	42666	79681669
Pneumonia	50.57	15.41	55	19998	660191	79064144
Abdominal distension	50.32	15.41	100	19953	119550	79604785
Product communication issue	49.66	15.41	16	20037	1053	79723282
Flank pain	48.28	15.41	40	20013	19804	79704531
Neutropenia	46.84	15.41	8	20045	287702	79436633
Toxicity to various agents	46.52	15.41	24	20029	421516	79302819
Mesenteric panniculitis	45.94	15.41	12	20041	373	79723962
Depressive symptom	45.12	15.41	25	20028	6398	79717937
Abdominal pain upper	44.95	15.41	141	19912	223678	79500657
Vision blurred	41.54	15.41	86	19967	105812	79618523
Lactic acidosis	41.31	15.41	68	19985	70291	79654044
Retinopathy	38.35	15.41	19	20034	3872	79720463
Appetite disorder	38.25	15.41	24	20029	7715	79716620
Acute kidney injury	38.17	15.41	242	19811	519162	79205173
Respiration abnormal	38.11	15.41	24	20029	7764	79716571
Death	37.26	15.41	53	20000	566461	79157874
Asthma	36.76	15.41	95	19958	135000	79589335
Necrotising myositis	35.53	15.41	13	20040	1255	79723080
Diabetes mellitus inadequate control	34.02	15.41	36	20017	24228	79700107
Myoglobinuria	33.52	15.41	12	20041	1088	79723247
Nasal congestion	33.40	15.41	65	19988	76487	79647848
Dyspepsia	33.32	15.41	80	19973	108607	79615728
Neuropathy vitamin B12 deficiency	32.79	15.41	7	20046	88	79724247
Disease progression	32.61	15.41	4	20049	184358	79539977
Thrombocytopenia	32.52	15.41	13	20040	265246	79459089
Pancreatitis necrotising	32.45	15.41	17	20036	3891	79720444
Thyroid mass	32.12	15.41	17	20036	3973	79720362
Vitamin B12 decreased	31.27	15.41	16	20037	3489	79720846
Febrile neutropenia	30.55	15.41	10	20043	230989	79493346
Vitreous haemorrhage	30.40	15.41	16	20037	3697	79720638
Respiratory failure	29.49	15.41	5	20048	180906	79543429
Gastrooesophageal reflux disease	29.07	15.41	74	19979	104172	79620163
Gastric ischaemia	28.61	15.41	5	20048	19	79724316
Pancreatic carcinoma metastatic	27.44	15.41	15	20038	3738	79720597
Synovitis	27.33	15.41	3	20050	150731	79573604
Rales	26.85	15.41	29	20024	19972	79704363
Pancytopenia	26.11	15.41	5	20048	165740	79558595
Anaemia	26.02	15.41	45	20008	444970	79279365
General physical health deterioration	25.71	15.41	19	20034	275219	79449116
Glomerular filtration rate decreased	25.50	15.41	30	20023	22672	79701663
Medullary thyroid cancer	25.49	15.41	7	20046	264	79724071
Impaired gastric emptying	25.45	15.41	21	20032	10332	79714003
Malignant neoplasm progression	23.92	15.41	3	20050	135987	79588348
Pleural effusion	23.71	15.41	4	20049	145258	79579077
Therapeutic product effect decreased	23.68	15.41	6	20047	163857	79560478
Drug abuse	23.42	15.41	6	20047	162685	79561650
Hospitalisation	23.32	15.41	64	19989	94172	79630163
Off label use	23.31	15.41	338	19715	906877	78817458
Platelet count decreased	23.11	15.41	10	20043	194654	79529681
Arthropathy	22.84	15.41	8	20045	177103	79547232
Urethral caruncle	22.66	15.41	5	20048	74	79724261
Maculopathy	22.64	15.41	12	20041	2813	79721522
Product label confusion	22.38	15.41	10	20043	1616	79722719
Pharyngeal swelling	21.84	15.41	17	20036	7702	79716633
Dizziness	21.82	15.41	215	19838	526226	79198109
Drug hypersensitivity	21.63	15.41	26	20027	298890	79425445
Irregular sleep phase	21.44	15.41	5	20048	96	79724239
Rheumatoid arthritis	21.34	15.41	13	20040	208457	79515878
Blood glucose abnormal	21.04	15.41	19	20034	10547	79713788
Increased appetite	20.88	15.41	20	20033	11958	79712377
Injection site extravasation	20.47	15.41	18	20035	9651	79714684
Stomatitis	20.03	15.41	6	20047	146751	79577584
Joint swelling	19.95	15.41	26	20027	288620	79435715
Hyperglycaemia	19.67	15.41	50	20003	70285	79654050
Urine calcium/creatinine ratio increased	19.54	15.41	5	20048	143	79724192
Leukopenia	19.48	15.41	3	20050	116510	79607825
Food aversion	19.46	15.41	8	20045	1055	79723280
Somnolence	19.26	15.41	19	20034	238962	79485373
Food craving	19.07	15.41	9	20044	1648	79722687
Therapeutic drug monitoring analysis incorrectly performed	18.80	15.41	7	20046	709	79723626
Illness	18.49	15.41	38	20015	46473	79677862
Amylase increased	18.20	15.41	18	20035	11191	79713144
Weight loss poor	18.11	15.41	8	20045	1258	79723077
Bradycardia	17.69	15.41	6	20047	135551	79588784
Oedema peripheral	17.15	15.41	23	20030	252265	79472070
Intentional overdose	17.11	15.41	3	20050	105957	79618378
Treatment failure	16.93	15.41	11	20042	170475	79553860
Glossodynia	16.52	15.41	3	20050	103334	79621001
Chronic kidney disease	16.44	15.41	45	20008	66109	79658226
Cholecystitis chronic	16.25	15.41	16	20037	9890	79714445
Impaired quality of life	16.14	15.41	19	20034	14367	79709968
Allodynia	16.10	15.41	8	20045	1640	79722695
Reperfusion arrhythmia	16.05	15.41	5	20048	295	79724040
Incorrect dose administered	16.02	15.41	49	20004	76581	79647754
Contraindicated product administered	15.87	15.41	10	20043	157528	79566807
Cardiac failure congestive	15.84	15.41	8	20045	142394	79581941
Contraindicated product prescribed	15.77	15.41	8	20045	1713	79722622
Product dispensing error	15.69	15.41	18	20035	13245	79711090
Cardio-respiratory arrest	15.62	15.41	4	20049	108506	79615829
Infection	15.47	15.41	23	20030	241689	79482646

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A10BJ06	ALIMENTARY TRACT AND METABOLISM DRUGS USED IN DIABETES BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS Glucagon-like peptide-1 (GLP-1) analogues
FDA CS	M0160181	Glucagon-Like Peptide 1
FDA MoA	N0000020058	Glucagon-like Peptide-1 (GLP-1) Agonists
FDA EPC	N0000178480	GLP-1 Receptor Agonist
CHEBI has role	CHEBI:35526	antidiabetic
CHEBI has role	CHEBI:63726	neuroprotective agents
CHEBI has role	CHEBI:71196	GLP-1 receptor agonist
CHEBI has role	CHEBI:74518	anti-obestic agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Diabetes mellitus type 2	indication	44054006	DOID:9352
Weight loss	indication	89362005
Obesity	indication	414916001	DOID:9970

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.23	acidic
pKa2	3.31	acidic
pKa3	3.71	acidic
pKa4	3.97	acidic
pKa5	4.22	acidic
pKa6	4.53	acidic
pKa7	4.76	acidic
pKa8	9.65	acidic
pKa9	12.06	acidic
pKa10	12.28	acidic
pKa11	12.41	acidic
pKa12	12.5	acidic
pKa13	12.63	acidic
pKa14	12.76	acidic
pKa15	12.95	acidic
pKa16	12.98	acidic
pKa17	13.11	acidic
pKa18	13.18	acidic
pKa19	13.24	acidic
pKa20	13.3	acidic
pKa21	13.4	acidic
pKa22	13.51	acidic
pKa23	13.61	acidic
pKa24	13.66	acidic
pKa25	13.73	acidic
pKa26	13.77	acidic
pKa27	13.83	acidic
pKa28	13.87	acidic
pKa29	13.94	acidic
pKa30	11.05	Basic
pKa31	10.45	Basic
pKa32	7.88	Basic
pKa33	5.98	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	RX	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	8536122	March 20, 2026	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8536122	March 20, 2026	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	8129343	Dec. 5, 2031	AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	8129343	Dec. 5, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	9278123	Dec. 16, 2031	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	RX	SOLUTION	SUBCUTANEOUS	10335462	June 21, 2033	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
2MG/3ML (0.68MG/ML)	OZEMPIC	NOVO	N209637	Oct. 6, 2022	RX	SOLUTION	SUBCUTANEOUS	10335462	June 21, 2033	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	10335462	June 21, 2033	A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	9764003	June 21, 2033	METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	10278923	May 2, 2034	METHOD OF TREATING TYPE 2 DIABETES MELLITUS
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	10888605	Aug. 24, 2038	METHOD FOR WEIGHT MANAGEMENT
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	11318191	Feb. 17, 2041	METHOD FOR WEIGHT MANAGEMENT

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
2MG/1.5ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	Dec. 5, 2017	RX	SOLUTION	SUBCUTANEOUS	Jan. 16, 2023	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
4MG/3ML (1.34MG/ML)	OZEMPIC	NOVO	N209637	April 9, 2019	RX	SOLUTION	SUBCUTANEOUS	Jan. 16, 2023	REDUCE THE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION OR NON-FATAL STROKE) IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE
14MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	Jan. 16, 2023	ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
3MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	Jan. 16, 2023	ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
7MG	RYBELSUS	NOVO	N213051	Sept. 20, 2019	RX	TABLET	ORAL	Jan. 16, 2023	ADDITION OF INFORMATION TO CLINICAL STUDIES SECTION REGARDING CARDIOVASCULAR OUTCOME
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	June 4, 2024	NEW PRODUCT
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	June 4, 2024	NEW PRODUCT
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	June 4, 2024	NEW PRODUCT
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	June 4, 2024	NEW PRODUCT
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	June 4, 2024	NEW PRODUCT
8MG/3ML (2.68MG/ML)	OZEMPIC	NOVO	N209637	March 28, 2022	RX	SOLUTION	SUBCUTANEOUS	March 28, 2025	ADDITION OF A 3RD MAINTENANCE DOSE OF SEMAGLUTIDE
0.25MG/0.5ML (0.25MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Dec. 23, 2025	NEW PATIENT POPULATION
0.5MG/0.5ML (0.5MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Dec. 23, 2025	NEW PATIENT POPULATION
1.7MG/0.75ML (1.7MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Dec. 23, 2025	NEW PATIENT POPULATION
1MG/0.5ML (1MG/0.5ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Dec. 23, 2025	NEW PATIENT POPULATION
2.4MG/0.75ML (2.4MG/0.75ML)	WEGOVY	NOVO	N215256	June 4, 2021	RX	SOLUTION	SUBCUTANEOUS	Dec. 23, 2025	NEW PATIENT POPULATION

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Glucagon-like peptide 1 receptor	GPCR	P43220	GLP1R_HUMAN	AGONIST	IC50	9.42		SCIENTIFIC LITERATURE	DRUG LABEL

External reference:

ID	Source
53AXN4NNHX	UNII
4037164	VANDF
C3885068	UMLSCUI
CHEBI:167574	CHEBI
CHEMBL2108724	ChEMBL_ID
56843331	PUBCHEM_CID
DB13928	DRUGBANK_ID
D10025	KEGG_DRUG
9113	INN_ID
9724	IUPHAR_LIGAND_ID
304634	MMSL
325192	MMSL
33346	MMSL
d08688	MMSL
017424	NDDF
764283003	SNOMEDCT_US
764284009	SNOMEDCT_US
1991302	RXNORM
C000591245	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4130	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4130	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4130	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4132	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4132	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4132	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4136	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4136	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4136	INJECTION, SOLUTION	1.34 mg	SUBCUTANEOUS	NDA	30 sections
Ozempic	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4181	INJECTION, SOLUTION	0.68 mg	SUBCUTANEOUS	NDA	30 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4303	TABLET	3 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4303	TABLET	3 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4303	TABLET	3 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4307	TABLET	7 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4307	TABLET	7 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4307	TABLET	7 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4314	TABLET	14 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4314	TABLET	14 mg	ORAL	NDA	29 sections
RYBELSUS	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4314	TABLET	14 mg	ORAL	NDA	29 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4501	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4501	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4501	INJECTION, SOLUTION	1 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4505	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4505	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4505	INJECTION, SOLUTION	0.50 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4517	INJECTION, SOLUTION	1.70 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4517	INJECTION, SOLUTION	1.70 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4517	INJECTION, SOLUTION	1.70 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4524	INJECTION, SOLUTION	2.40 mg	SUBCUTANEOUS	NDA	32 sections
WEGOVY	HUMAN PRESCRIPTION DRUG LABEL	1	0169-4524	INJECTION, SOLUTION	2.40 mg	SUBCUTANEOUS	NDA	32 sections